288 related articles for article (PubMed ID: 35347544)
1. Review on NAD(P)H dehydrogenase quinone 1 (NQO1) pathway.
Preethi S; Arthiga K; Patil AB; Spandana A; Jain V
Mol Biol Rep; 2022 Sep; 49(9):8907-8924. PubMed ID: 35347544
[TBL] [Abstract][Full Text] [Related]
2. Implications of NQO1 in cancer therapy.
Oh ET; Park HJ
BMB Rep; 2015 Nov; 48(11):609-17. PubMed ID: 26424559
[TBL] [Abstract][Full Text] [Related]
3. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.
Belinsky M; Jaiswal AK
Cancer Metastasis Rev; 1993 Jun; 12(2):103-17. PubMed ID: 8375015
[TBL] [Abstract][Full Text] [Related]
5. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.
Dinkova-Kostova AT; Talalay P
Arch Biochem Biophys; 2010 Sep; 501(1):116-23. PubMed ID: 20361926
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones.
Glorieux C; Sandoval JM; Dejeans N; Ameye G; Poirel HA; Verrax J; Calderon PB
Life Sci; 2016 Jan; 145():57-65. PubMed ID: 26687450
[TBL] [Abstract][Full Text] [Related]
7. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
8. Protection of NAD(P)H:quinone oxidoreductase 1 against renal ischemia/reperfusion injury in mice.
Gang GT; Hwang JH; Kim YH; Noh JR; Kim KS; Jeong JY; Choi DE; Lee KW; Jung JY; Shong M; Lee CH
Free Radic Biol Med; 2014 Feb; 67():139-49. PubMed ID: 24189322
[TBL] [Abstract][Full Text] [Related]
9. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
[TBL] [Abstract][Full Text] [Related]
10. NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.
Singh S; Zahid M; Saeed M; Gaikwad NW; Meza JL; Cavalieri EL; Rogan EG; Chakravarti D
J Steroid Biochem Mol Biol; 2009 Oct; 117(1-3):56-66. PubMed ID: 19628038
[TBL] [Abstract][Full Text] [Related]
11. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
Pey AL; Megarity CF; Timson DJ
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535
[TBL] [Abstract][Full Text] [Related]
12. Jun and Fos regulation of NAD(P)H: quinone oxidoreductase gene expression.
Jaiswal AK
Pharmacogenetics; 1994 Feb; 4(1):1-10. PubMed ID: 8004128
[TBL] [Abstract][Full Text] [Related]
13. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
14. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
[TBL] [Abstract][Full Text] [Related]
15. Induction of NAD(P)H-quinone oxidoreductase 1 by antioxidants in female ACI rats is associated with decrease in oxidative DNA damage and inhibition of estrogen-induced breast cancer.
Singh B; Bhat NK; Bhat HK
Carcinogenesis; 2012 Jan; 33(1):156-63. PubMed ID: 22072621
[TBL] [Abstract][Full Text] [Related]
16. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
18. Interactions of the antioxidant enzymes NAD(P)H: Quinone oxidoreductase 1 (NQO1) and NRH: Quinone oxidoreductase 2 (NQO2) with pharmacological agents, endogenous biochemicals and environmental contaminants.
Rashid MH; Babu D; Siraki AG
Chem Biol Interact; 2021 Aug; 345():109574. PubMed ID: 34228969
[TBL] [Abstract][Full Text] [Related]
19. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H:quinone oxidoreductase (NQO1) and oxidative stress.
Nemeikaite-Ceniene A; Sarlauskas J; Anusevicius Z; Nivinskas H; Cenas N
Arch Biochem Biophys; 2003 Aug; 416(1):110-8. PubMed ID: 12859987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
